Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually
New filtration lines will boost global drug supply and strengthen India’s role in Merck’s manufacturing network
Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
Recognition across subsidiaries and geographies highlights pharma major’s focus on inclusive culture, employee experience, and global workforce development
Health of the Nation 2026, based on over 3 million assessments, finds rising diabetes, obesity, and hidden cardiac risks in under-30s and working professionals
Sharp increase in diabetes, hypertension and fatty liver in 30–50 age group
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
